<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): May 5, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>ImaRx Therapeutics, Inc.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>001-33043</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>86-0974730</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>12277 134th Court NE, Suite 202<BR>Redmond, WA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>98052</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(425) 821-5501</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>N/A<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt">ITEM 4.01 CHANGES IN REGISTRANT&#146;S CERTIFYING ACCOUNTANT


<P align="justify" style="font-size: 10pt">(a)&nbsp;Resignation of independent registered public accounting firm


<P align="justify" style="font-size: 10pt">In connection with the reorganization of McKennon, Wilson &#038; Morgan LLP (the &#147;Former Auditors&#148;), certain of its audit
partners resigned and joined a new accounting firm called DBBMcKennon. As a result, the Former Auditors resigned as
the independent auditors of ImaRx Therapeutics, Inc. (the &#147;Company&#148;) effective May&nbsp;5, 2009. &nbsp;The Former Auditors had
been the Company&#146;s auditor since December&nbsp;19, 2008. &nbsp;


<P align="justify" style="font-size: 10pt">The Audit Committee of the Company&#146;s Board of Directors approved the resignation of the Former Auditors.


<P align="justify" style="font-size: 10pt">The Former Auditors&#146; audit report on the Company&#146;s financial statements for each of the past two fiscal years did not
contain an adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope
or accounting principles, except that the Former Auditors&#146; report on the Company&#146;s financial statements for each of the
past two fiscal years included an explanatory paragraph describing the uncertainty as to the Company&#146;s ability to
continue as a going concern.


<P align="justify" style="font-size: 10pt">During the fiscal years ended December&nbsp;31, 2008 and 2007 and through May&nbsp;5, 2009, (a)&nbsp;there were no disagreements
between the Company and the Former Auditors on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the Former
Auditors, would have caused the Former Auditors to make reference to the subject matter of the disagreement in
connection with its reports on the financial statements for such years; and (b)&nbsp;no reportable events as set forth in
Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K have occurred.


<P align="justify" style="font-size: 10pt">The Company provided the Former Auditors with a copy of the disclosures it is making in response to Item 304(a) of
Regulation&nbsp;S-K in this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the
&#147;SEC&#148;) and requested that the Former Auditors furnish it with a letter addressed to the SEC stating whether the Former
Auditors agree with the above statements, and if not, stating the respects in which it does not agree. &nbsp;A copy of such
letter, dated May&nbsp;5, 2009, is filed as Exhibit&nbsp;16.1 hereto.


<P align="justify" style="font-size: 10pt">(b)&nbsp;Engagement of new independent registered public accounting firm.


<P align="justify" style="font-size: 10pt">Effective May&nbsp;5, 2009, the Audit Committee of the Company&#146;s Board of Directors appointed DBBMcKennon (the &#147;New
Auditors&#148;) as the Company&#146;s new independent auditors.


<P align="justify" style="font-size: 10pt">During the fiscal years ended December&nbsp;31, 2008 and 2007 and through May&nbsp;5, 2009, neither the Company nor anyone acting
on its behalf consulted with the New Auditors regarding any of the matters or events set forth in Item&nbsp;304(a)(2)(i) and
(ii)&nbsp;of Regulation&nbsp;S-K.

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt">ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS


<P align="justify" style="font-size: 10pt; text-indent: 4%">Exhibits


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Letter on change in certifying accountant from McKennon, Wilson &#038; Morgan LLP dated May&nbsp;5, 2009.</DIV></TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt">SIGNATURES



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: May&nbsp;11, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ImaRx Therapeutics, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u>/s/ Bradford A. Zakes</u></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By: Bradford A. Zakes</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c85234e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10327}]
{"company-data": {"conformed-name": "IMARX THERAPEUTICS INC", "cik": "0001123695", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33043", "film-number": "09814494"}, "business-address": {"street1": "1730 EAST RIVER ROAD", "street2": "SUITE 200", "city": "TUSCON", "state": "AZ", "zip": "85718", "phone": "520-770-1259"}, "mail-address": {"street1": "1730 EAST RIVER ROAD", "street2": "SUITE 200", "city": "TUSCON", "state": "AZ", "zip": "85718"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2009
ImaRx Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-33043
86-0974730
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
12277 134th Court NE, Suite 202
Redmond, WA
98052
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(425) 821-5501
N/A
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
(a) Resignation of independent registered public accounting firm
In connection with the reorganization of McKennon, Wilson & Morgan LLP (the "Former Auditors"), certain of its audit
partners resigned and joined a new accounting firm called DBBMcKennon. As a result, the Former Auditors resigned as
the independent auditors of ImaRx Therapeutics, Inc. (the "Company") effective May 5, 2009.  The Former Auditors had
been the Company's auditor since December 19, 2008.
The Audit Committee of the Company's Board of Directors approved the resignation of the Former Auditors.
The Former Auditors' audit report on the Company's financial statements for each of the past two fiscal years did not
contain an adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope
or accounting principles, except that the Former Auditors' report on the Company's financial statements for each of the
past two fiscal years included an explanatory paragraph describing the uncertainty as to the Company's ability to
continue as a going concern.
During the fiscal years ended December 31, 2008 and 2007 and through May 5, 2009, (a) there were no disagreements
between the Company and the Former Auditors on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the Former
Auditors, would have caused the Former Auditors to make reference to the subject matter of the disagreement in
connection with its reports on the financial statements for such years; and (b) no reportable events as set forth in
Item 304(a)(1)(v) of Regulation S-K have occurred.
The Company provided the Former Auditors with a copy of the disclosures it is making in response to Item 304(a) of
Regulation S-K in this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the
"SEC") and requested that the Former Auditors furnish it with a letter addressed to the SEC stating whether the Former
Auditors agree with the above statements, and if not, stating the respects in which it does not agree.  A copy of such
letter, dated May 5, 2009, is filed as Exhibit 16.1 hereto.
(b) Engagement of new independent registered public accounting firm.
Effective May 5, 2009, the Audit Committee of the Company's Board of Directors appointed DBBMcKennon (the "New
Auditors") as the Company's new independent auditors.
During the fiscal years ended December 31, 2008 and 2007 and through May 5, 2009, neither the Company nor anyone acting
on its behalf consulted with the New Auditors regarding any of the matters or events set forth in Item 304(a)(2)(i) and
(ii) of Regulation S-K.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibits
16.1
Letter on change in certifying accountant from McKennon, Wilson & Morgan LLP dated May 5, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Dated: May 11, 2009
ImaRx Therapeutics, Inc.
/s/ Bradford A. Zakes
By: Bradford A. Zakes
President and Chief Executive Officer